GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal …
Oct 14, 2024 · On Monday, GSK plc (NYSE: GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic...
Sanofi US News
Sep 13, 2024 · The US Food and Drug Administration (FDA) has approved DUPIXENT (dupilumab) as an add-on maintenance treatment for adolescent patients aged 12 to 17 years with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). This approval expands the initial FDA approval in CRSwNP from June …
Patients with CRSwNP see smaller nasal polyps, less congestion …
Dec 18, 2024 · Patients with severe chronic rhinosinusitis with nasal polyps experienced significant improvements in their symptoms with tezepelumab-ekko compared with placebo, according to a press release from...
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL …
Nov 8, 2024 · WAYPOINT was a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of TEZSPIRE administered subcutaneously in adults with severe CRSwNP.
Dupixent receives FDA approval as first CRSwNP treatment
Sep 16, 2024 · The US Food and Drug Administration (FDA) has expanded the approval of Dupixent (dupilumab) to include adolescents aged 12 to 17 years with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).
GSK’s Nucala Gains Approval in China for CRSwNP - Yahoo Finance
Jan 3, 2025 · GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30...
Tezspire met both co-primary endpoints in the Phase III …
Nov 8, 2024 · Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that AstraZeneca and Amgen’s Tezspire (tezepelumab) demonstrated a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion ...
GSK Announces Positive Phase III Results from ANCHOR Trials for ...
14 October 2024 -- GSK plc (LSE/NYSE: GSK) today announced positive headline results from the phase III clinical trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with CRSwNP.
Dupilumab (Dupixent) becomes first FDA-approved drug for adolescent CRSwNP
Sep 13, 2024 · The US Food and Drug Administration (FDA) expanded the approval of type 2 inflammation-targeting biologic dupilumab (Dupixent) to include patients aged 12 – 17 years old with chronic rhinosinusitis with nasal polyps (CRSwNP).
Dupilumab for Chronic Rhinosinusitis With Nasal Polyps Is Effective
Dec 2, 2024 · Dupilumab was effective for patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) at 52 weeks, researchers reported in the Journal of Allergy and Clinical Immunology. Researchers conducted an observational, retrospective study evaluating the effectiveness of dupilumab in a large-scale CRSwNP cohort from 6 tertiary